MAPT and Alzheimer disease: We thus suggest that soluble p-tau levels may be an optimal treatment target for attenuating tau aggregation and subsequent cognitive decline in the earliest stages of AD, prior to the development of widespread insoluble fibrillar tau aggregates and dementia, which will be critical for the design of future clinical trials.